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Abstract
Background: Transmembrane protein 158 (TMEM158) is a recently identified upregulated gene during Ras-induced
senescence. Its association with various cancers has been recently reported. However, the expression and biological
function of TMEM158 in ovarian cancer is still unclear. This study was aimed to elucidate the roles of TMEM158 in
cell proliferation, adhesion and cell invasion of ovarian cancer cells.
Methods: We analyzed TMEM158 mRNA level in ovarian cancer tissues and adjacent no-tumorous tissues by real-time
PCR. We then suppressed TMEM158 expression of ovarian cancer cells by RNA interference and examined the effects of
TMEM158 knockdown on cancerous transformation of ovarian cancer cells.
Results: The RNA-sequencing data of the ovarian cancer cohort from The Cancer Genome Atlas project (TCGA) and our
real-time PCR data showed that TMEM158 was overexpressed in ovarian cancer. Knockdown of TMEM158 by RNA
interference in ovarian cancer cells significantly inhibited cell proliferation, which may be due to the increase of G1-phase
arrest. Silencing of TMEM158 also inhibited cell adhesion, cell invasion as well as tumorigenicity in nude mice. Moreover,
knockdown of TMEM158 notably repressed cell adhesion via down-regulating the expression intercellular adhesion
molecule1 (ICAM1) and vascular cell adhesion molecule1 (VCAM1). Transforming Growth Factor-β (TGF-β) signaling
pathway was also remarkably impaired by TMEM158 silencing.
Conclusions: Our data suggests that TMEM158 may work as an oncogene for ovarian cancer and that inhibition of
TMEM158 may be a therapeutic strategy for ovarian cancer.
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Introduction
Ovarian cancer is the most lethal type of gynecologic
malignancy [1]. Due to its insidious onset, ovarian cancer
is often diagnosed in advanced stages, resulting in a poor
survival rate [2]. The five-year survival of patients with
ovarian cancer is almost 30 % and has not significantly
changed over the past 30 years regardless of important
advances in surgery, radiation and chemotherapy [3–7].
This emphasizes the need for new diagnosis markers and
therapies based on a well understanding of the molecular
mechanisms underlying the oncogenesis and development
of ovarian cancer.
Transmembrane protein 158 (TMEM158) was identified
as an upregulated gene during Ras-induced senescence in
human diploid fibroblasts infected with a RasV12-
containing retrovirus and also known as Ras-induced
senescence 1(RIS-1) [8]. In a non-small cell lung cancer
(NSCLC) line transfected with the gene TLSC1,
TMEM158 expression was found upregulated and tumor
properties of the cells were suppressed [9]. There are a
few studies concerned about the expression and functions
of TMEM158 in tumors [10–12]. Gene expression ana-
lysis of ductal carcinoma showed that TMEM158 expres-
sion was not detected in tumor cells, but its expression
was observed in the immediately adjacent stromal cells
[11]. TMEM158 was overexpressed in Wilms tumors with
somatic CTNNB1 mutations, suggesting a relationship
between the Ras and Wnt signaling pathways [12].
TMEM158 has recently been identified as a target gene in
the mutator pathway of microsatellite instability (MSI)-
positive colorectal cancers. Low frequency MSI tumors
with TMEM158 mutated usually were associated with a
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worse prognosis [10]. However, little is known about the
expression pattern and biological functions of THEM158
in ovarian cancers.
To investigate the roles of TMEM158 in ovarian cancer,
we determined its expression in ovarian cancer and nor-
mal tissues. The effects of TMEM158 knockdown in the
proliferation, adhesion and invasion of ovarian cancer cells
were assessed. The involved possible mechanism was also
explored. Our study provides original documentation for
the overexpression of TMEM158 in ovarian cancer and it
may be an effective therapeutic target for this disease.
Materials and methods
Bioinformatics analysis
From The Cancer Genome Atlas (TCGA, https://tcga-
data.nci.nih.gov/tcga/), we collect expression data of 568
ovarian cancers and 8 adjacent normal tissues. TMEM158
expression was shown to be statistically normally distrib-
uted by Shapiro-Wilk test. Levene’s test indicated hetero-
geneous variances of TMEM158 expression among ovarian
cancers and normal tissues (P < 0.001).
To further investigate the biological pathways involved
in ovarian cancer pathogenesis through TMEM158
pathway, we performed a gene set enrichment analysis
(GSEA) [13, 14]. The KEGG gene sets biological process
database (c2.KEGG.v4.0) were used for enrichment
analysis.
Cancer specimens
Tumor tissues and paired noncancerous tissues were
collected from 25 patients diagnosed with Stage II/III
epithelial ovarian serous adenocarcinoma, who were ad-
mitted to Department of Obstetrics and Gynecology,
Yangpu Hospital, Tongji University (Shanghai, China)
between 2010 and 2013. Written informed consent was
obtained from all patients prior to participation on the
study. The ethics committee of Tongji University (Shang-
hai, China) approved the design and informed consent.
Cell lines
All culture media contained 10 % fetal bovine serum (FBS,
Life Technologies), 100 mg/ml penicillin G, and 50 μg/ml
streptomycin (Life Technologies). All cell lines were from
American Type Culture Collection. The ovarian cancer
cell lines OVCAR3, A2780 and HO-8910 cells were cul-
tured in RPMI 1640 (Life Technologies). The CAOV3,
SK-OV-3 and HEK 293T cells were cultured in DMEM
(Life Technologies). All cells were maintained at 37 °C in
5 % CO2.
RNA extraction and Real-time PCR
Total RNA was extracted using TRIzol Reagent (Invitro-
gen) according to the manufacturer’s instructions. Com-
plementary DNA was synthesized with CDNA synthesis
kit (Thermo Fisher Scientific). Real-time PCR was per-
formed to detect mRNA levels of indicated genes. GAPD
H was served as an internal control. The primers used
were list as follows: TMEM158, 5′-TGTGCTTCGTGCT
GTAGTTATC-3′ and 5′- TCAGTCCAAGGGCTTAAAC
ATC-3′; GAPDH, 5′- AATCCCATCACCATCTTC -3′
and 5′-AGGCTGTTGTCATACTTC-3′; transforming
Growth Factor-β (TGF-β), 5′- GACTACTACGCCAAGG
AGGTC-3′ and 5′-GAGAGCAACACGGGTTCAG-3′;
bone morphogenetic protein 4 (BMP4), 5′- CTGACCAC
CTCAACTCAAC -3′ and 5′-ACCCACATCCCTCTA
CTAC -3′; intercellular adhesion molecule1 (ICAM1), 5′-
GTTGTTGGGCATAGAGAC-3′ and 5′- CAGGGCAGT
TTGAATAGC-3′; vascular cell adhesion molecule1 (VC
AM1), 5′-TGGGAACGAACACTCTTAC-3′ and 5′-
CAGCAACTGAACACTTGAC - 3′. All reactions were
conducted on an ABI 7300 real-time PCR machine
(Applied Biosystems) using the following cycling pa-
rameters, 95 °C for 10 min, followed by 40 cycles of
95 °C for 15 s, 60 °C for 45 s. The gene expression was
calculated using the ΔΔ Ct method. All data represent
the average of three replicates.
RNA interference and construction of stable cell line
Three shRNAs targeting position 1520 − 1540 (AAATG
ACCAAATCCTGTGTAT; named TMEM158-Ri-1), pos-
ition 1627 − 1647 (TAAGAGAAGCTCTTTGTATCT;
named TMEM158-Ri-2) and position 1719 − 1739 (TAAC
ACCGATATATTGTTACC; named TMEM158-Ri-3) of
human TMEM158 mRNA were cloned into a lentiviral
vector (PLKO.1). A non-specific scramble shRNA se-
quence (CCTAAGGTTAAGTCGCCCTCG) was used as
negative control. The constructs were then transfected
into HEK293T cells with lentiviral packaging vectors by
using lipofectamine 2000 (Invitrogen) according to the
manufacture’s instruction. Viruses were collected 48 h
after transfection and used to infect A2780 cells and
HO-8910 cells. Stable cell line was generated by puromycin
(Sigma) selection.
Western blot
Total cell lysates were collected with radioimmunoprecipi-
tation assay buffer (50 mmol/l Tris-HCl, 150 mmol/l
NaCl, 1 % Triton X-100, 0.1 % SDS, 1 % deoxycholic acid
sodium). Protein concentration was measured by BCA
protein assay kit (Thermo Fisher Scientific). The super-
natants with equal amounts of protein were separated
on SDS-PAGE gels followed by electroblotting to
nitrocellulose membranes. Western blot analysis was
then carried out with appropriate primary and horseradish
peroxidase-conjugated secondary antibodies. Membranes
were developed with enhanced chemiluminescence (Bio-
Rad). Antibodies against TMEM158, TGFβ1, BMP4,
ICAM1 and VCAM1 were purchased from Abcam.
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GAPDH antibody was from CST Biotech. (Danvers,
MA, USA). GAPDH was served as an internal control.
The band intensity was measured using ImageJ soft-
ware (National Institutes of Health).
Cell proliferation assay
Cell proliferation was detected by using the Cell Count
Kit-8 (CCK-8, Dojindo Laboratories). Briefly, indicated
cells were plated onto 96-well plates (3 × 103 cells per
well). At indicated time point, CCK8 solution (10 μl in
100μl DMEM medium) was added to each well and in-
cubated for 1 h. Optical density values (OD) was mea-
sured at wavelength 450 nm by a microplate reader
(Bio-Rad). Each assay was carried out in triplicate.
Cell cycle analysis
The cell cycle was evaluated by flow cytometry using pro-
pidium iodide (PI, Sigma, St. Louis, MO, USA) staining on
a flow cytometer (BD Biosciences). Briefly, indicated cells
were plated in 6-well plates. The cells were collected and
fixed in 70 % ethanol at -20 °C overnight after 24 h cul-
ture. Cells were then washed in PBS and resuspended in
staining solution containing 20 μg/ml PI and 200 μg/ml
RNAse A. Experiments were performed in triplicate and
3 × 104 cells were analyzed per sample. G1, S, and G2/M
fractions were quantified using CellQuest software (BD
Biosciences) and manual gating. Each assay was carried
out in triplicate.
Cell adhesion assay
The adhesion assay was performed in 12-well plates. The
plates were pre-coated with 1 ml of fibronectin (5 μg/ml)
for 2 h at room temperature. Cells were seeded into the
coated plates at a density of 105 cells per well and allowed
to adhere at 37 °C for 1 h. Nonadherent cells were washed
off with phosphate-buffered saline (PBS) and fixed in 4 %
paraformaldehyde and stained with GIEMSA solution.
The number of adherent cells determined as described
previously [15]. Each assay was carried out in triplicate.
In vitro invasion assay
The upper well of the transwell (Corning, NY, USA) was
coated with Matrigel (BD Biosciences) at 37 °C in a 5 %
CO2 incubator for 1 h. Indicated cells were serum starved
for 24 h, and then 500 μl of cell suspension containing 105
cells/ml were placed in the upper compartment of the
chamber. Culture medium supplemented with 10 % FBS
(750 μl) was added into the lower well of the chamber.
The plates were incubated for 48 h. At the end of the in-
cubation, the cells on the upper surface of the filter were
completely removed by wiping with a cotton swab. Cells
that migrated into the lower well were washed with PBS,
fixed in 4 % paraformaldehyde and stained by 0.2 % crystal
violet. Cells were photographed and counted under mi-
croscopy. Each assay was carried out in triplicate.
In vivo tumorigenicity assay
Male BALB/c nude mice aged 4 − 5 weeks old were pur-
chased from Shanghai Laboratory Animal Company. The
mice were housed in a pathogen-free animal facility and
randomly assigned to the control or experimental group
(five mice per group). For each cell line, 2 × 106 cells were
resuspended in 200μl medium and subcutaneously
injected into the nude mice. Tumor formation was moni-
tored every three or four days by measuring the largest
and the smallest diameter of the formed tumors, and the
volume of the tumors was calculated using the following
formula: volume = 1/2 × (largest diameter) × (smallest
diameter)2. At euthanasia, the tumors were recovered
and the wet weights of each tumor were examined.
Animal care practices and all experiments were reviewed
and approved by the Committee on the Ethics of Animal
Experiments of Tongji University (Shanghai, China).
Statistical analysis
The data were analyzed using the two-tailed Student’s
t-test to calculate the statistical significance of differ-
ence between groups. The results were presented as the
mean value ± SEM. Statistically significant differences
were defined as having a P < 0.05.
Results
TMEM158 was overexpressed in ovarian cancer
To explore the expression of TMEM158 in ovarian can-
cer, we compared its expression by analyzing high
throughput RNA-sequencing data of the ovarian cancer
cohort from The Cancer Genome Atlas project (TCGA,
https://tcga-data.nci.nih.gov/tcga/). As shown in Fig. 1a,
TMEM158 expression was significantly increased in ovar-
ian cancer tissues as compared with the adjacent tissues,
which indicated that TMEM158 may be an oncogene in
ovarian cancer.
To further determine TMEM158 expression in ovarian
cancer, we performed real-time PCR analysis on 25 pairs
of ovarian cancer and their matched noncancerous tissue
samples. An overexpression of TMEM158 was found in
84 % (21/25) of tested ovarian cancer tissues (Fig. 1b).
Statistical analysis using the student’s t-test showed that
TMEM158 mRNA was significantly overexpressed in
ovarian tumor tissues when compared with normal tissues
(P < 0.001).
TMEM158 was down-regulated by RNA interference
(RNAi) in ovarian cancer cells
We then detected the protein and mRNA levels of
TMEM158 in five ovarian cancer cell lines by Western
blotting and real-time PCR, respectively. A high level of
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TMEM158 was observed in HO-8910 and A2780 cells
(Fig. 2a). Therefore, these two cells were chosen for the
following assays.
To investigate the functions of TMEM158 on ovarian
cancer, shRNA plasmids were constructed for the
suppressing of TMEM158 expression. Three pairs of
human TMEM158 gene shRNA sequences and negative
control (NC, a non-specific scramble shRNA sequence)
were cloned into a lentiviral plasmid. The recombinant
lentivirus was packaged in HEK293T cells. HO-8910
and A2780 cells were then infected with TMEM158-
RNAi or NC virus. The silencing effect of TMEM158-
RNAi were validated in HO-8910 (Fig. 2b) and A2780
cells (Fig. 2c) by Western-blotting and real-time PCR.
Our results indicated that TMEM158-Ri-1 was the
most efficient one and chosen for the further assays.
Down-regulation of TMEM158 inhibited cell proliferation
and induced G1-phase cell cycle arrest in ovarian cancer
cells
To substantiate the role of TMEM158 downregulation on
cell proliferation, we detected the proliferation of ovarian
cells infected with TMEM158-Ri-1 by using CCK-8 assay. As
shown in Fig. 3a and b, cell growth was remarkably impaired
in TMEM158-Ri-1 virus-infected cells (TMEM158-Ri-1)
compared to wild-type cells (WT) and scramble shRNA
virus-infected cells (NC). Our data suggested that TMEM158
Fig. 1 Overexpression of TMEM158 in ovarian cancer. (a) RNA-Seq analysis of TMEM158 mRNA expression in ovarian cancer and normal tissues. RNA-Seq
analysis used data download from TCGA. ** P value < 0.01. (b) The mRNA level of TMEM158 in 25 pairs of ovarian tumor and normal tissue was detected
by real-time PCR. Positive log2 (Tumor/Normal) on the y-axis indicated increased expression of TMEM158 in tumor tissue while negative log2 indicated
decreased expression of TMEM158 in tumor tissue. TMEM158 mRNA was significantly overexpressed in ovarian tumor tissues as compared with normal
tissues (P< 0.001)
Fig. 2 TMEM158 expression was suppressed by RNAi in ovarian cancer cells. (a) TMEM158 expression in five ovarian cancer cell lines was
detected by Western blotting and real-time PCR. GAPDH was used as internal control. Highest expression of TMEM158 were observed in
A2780 and HO-8910 cells, which were chosen for further analysis. Western blot (upper panel) and real-time PCR (lower panel) analysis
showing the efficiency of TMEM158 knockdown in HO-8910 (b) and A2780 cells (c). WT: wild type cells; NC: scrambled shRNA virus
infected cells; Ri-1, Ri-2 and Ri-3: TMEM158-shRNA-1, -2 and -3 virus infected cells
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was involved in the regulation of ovarian cancer cell
proliferation.
The possible inhibitory effect of TMEM158 knockdown
on cell cycle progression was then determined. As shown
in Fig. 3c, downregulation of TMEM158 expression re-
sulted in a higher number of HO-8910 cells in the G1
phase (65.4 % ± 1.5 %), compared with WT cells (42.1 % ±
1.6 %) and NC cells (40.9 % ± 1.2 %). Similar results were
observed in A2780 cells (Fig. 3d). Our data suggested that
TMEM158 knockdown notably induced G1-phase cell
cycle arrest in ovarian cancer cells, which may lead to the
inhibition of cell proliferation.
TMEM158 knockdown inhibited cell adhesion
The effects of TMEM158 on cell adhesion capacity were
evaluated by cell adhesion assay (Fig. 4a and b). The
adherent ability to fibronectin was significantly inhibited
in ovarian cells by TMEM158 knockdown. The number of
adherent TMEM158-Ri-1 cells was reduced to 35 % of
that of NC cells when HO-8910 cells were used (Fig. 4a
and b). Similar results were obtained in A2780 cells. These
data suggested a role of TMEM158 in ovarian cancer cell
adhesion.
Suppressing TMEM158 expression inhibited the
invasiveness of ovarian cancer cells
To explore whether TMEM158 affected the invasive abil-
ity of ovarian cancer cells, Matrigel-coated membranes
chamber invasion assay was carried out. Dramatically re-
duced invasive ability was observed in TMEM158 knock-
down cells compared to control cells. The number of
invaded TMEM158-Ri-1 cells was decreased to 58 % of
that of NC cells when HO-8910 cells were used (Fig. 4c
and d). Similar results were observed in A2780 cells.
Fig. 3 TMEM158 knockdown impaired cell proliferation and cell cycle in HO-8910 (a and c) and A2780 cells (b and d). Results of CCK-8
assay performed in control cells and TMEM158 knockdown cells were shown in (a and b). The percentage of cells in G1, S and G2-M
phase for each sample at 48 h after viral infection were shown in (c and d). Data were based on at least 3 independent experiments,
and shown as mean ± SEM. WT: wild type cells; NC: scrambled shRNA virus infected cells; TMEM158-Ri-1: TMEM158-shRNA-1 virus infected
cells. Data were shown as the mean value ± SEM. **P < 0.01, as compared with NC cells
Cheng et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:75 Page 5 of 9
Fig. 4 TMEM158 knockdown inhibited cell adhesion and cell invasion. We performed cell adhesion and invasion assay in fibronectin pre-coated plates
and Matrigel-coated transwell chambers, respectively. Adherent cells or invaded cells were stained, photographed and counted. Representative images
were shown in (a) and (c). Quantitative results of cell adhesion assay and invasion assay were shown in (b) and (d), respectively. Data were based on at
least 3 independent experiments, and shown as mean ± SEM. WT: wild type cells; NC: scrambled shRNA virus infected cells; TMEM158-Ri-1:
TMEM158-shRNA-1 virus infected cells. Data were shown as the mean value ± SEM. *P < 0.05, **P < 0.01 as compared with NC cells
Fig. 5 Knockdown of TMEM158 in HO-8910 cells inhibited tumorigenicity in nude mice. (a) An equal number of cells (NC and TMEM158-Ri-1)
were inoculated subcutaneously into nude mice. Tumor volume was estimated based on the following equation: volume = 1/2 × (largest diameter)
× (smallest diameter) 2. The mean value ± SEM. were from five animals in each group. (b) The nude mice with tumor formations. (c) Photograph of
tumors derived from NC and TMEM158-Ri-1 cells in nude mice. (d) Weights of tumors. *P < 0.01 as compared with NC cells
Cheng et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:75 Page 6 of 9
TMEM158 knockdown inhibits ovarian cancer growth in
nude mice xenograft model
Next, we determined whether knockdown of TMEM158
in ovarian cells could reduce tumor growth in vivo.
HO-8910 cells stable transfected with scramble shRNA
control or TMEM158-Ri-1 were subcutaneously injected
in athymic nude mice as previously described [16], and
tumor volumes were measured for 45 days. As shown in
Fig. 5, the TMEM158-Ri-1 treated tumors grew slower
than the control tumors in mice and the volume as well as
weight was half that of control tumors. These data
suggested that knockdown of TMEM158 inhibited tumor
growth in nude mice.
TMEM158 was positively correlated with TGF-β signaling
pathway and cell adhesion molecules
The exact pathway that TMEM158 may regulate in ovar-
ian cancers remains unclear. To probe the TMEM158-
associated pathways on an unbiased basis, we performed
GSEA using high throughput RNA-sequencing data of the
ovarian cancer cohort from TCGA. Among all the 188
predefined ‘KEGG pathways’ gene sets, TGF-β signaling
Fig. 6 Effect of TMEM158 knockdown on the protein expressions of TGF-β1, BMP4, ICAM1 and VCAM1. (a, b) Identification of TGF-β signaling pathway
and Cell adhesion genes as regulatory targets of TMEM158. Gene-set enrichment analysis (GSEA) identified significant association between TMEM158
and TGF-β signaling pathway or Cell adhesion genes in TCGA ovarian cancer dataset. Western blot (upper panel) and Real-time PCR (lower panel)
analysis identified that expression of TGF-β1, BMP4, ICAM1 and VCAM1 was significantly decreased by TMEM158 RNAi in HO-8910 (c) and A2780 cells
(d). Data were based on at least 3 independent experiments, and shown as mean ± SEM. **P < 0.01, as compared with NC cells
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pathway (Fig. 6a) and cell adhesion molecules (Fig. 6b)
was identified to be closely correlated with TMEM158
expression in the TCGA ovarian cancer dataset. Gene
expression of important regulators in TGF-β signaling
pathway and cell adhesion molecules was determined both
in mRNA and protein levels (Fig. 6c and d). The expres-
sion of TGF-β, BMP4, ICAM1 and VCAM1 was remark-
ably decreased after downregulation of TMEM158.
Discussion
Several investigation have been reported regarding the
expression and functions of TMEM158 in different tu-
mors [9–12]. In the present study, analysis using high
throughput RNA-sequencing data from TCGA demon-
strated a higher expression of TMEM158 in ovarian can-
cer compared to normal tissues (Fig. 1a). We then found
that TMEM158 mRNA expression was elevated in 84 %
(21/25) of tested ovarian cancer tissues by real-time
PCR (Fig. 1b). To further investigate the functions of
TMEM158 in ovarian cancer, we suppressed the ex-
pression of TMEM158 in two ovarian cells, HO-8910
and A2780 cells by RNA interference (Fig. 2b and c).
Our data showed that suppressing of TMEM158 ex-
pression notably inhibited the proliferation, cell cycle
progression (Fig. 3), adhesion, invasion (Fig. 4) and
tumorigenicity of ovarian cells (Fig. 5). Taken together,
our data further indicated contribution of TMEM158 in
ovarian cell carcinogenesis.
The regulation of cell cycle is frequently abnormal in
most common malignancies, resulting in aberrant cell
proliferation [17, 18]. Here, silencing of TMEM158 in
ovarian cancer cells significantly promoted cell arrest in
G1-phase (Fig. 3c and d), which may lead to the inhib-
ition of cell proliferation (Fig. 3a and b). Our results
were consistent with the previous study that found that
TMEM158 was an upregulated gene in Ras-senescent
human fibroblasts and expected to negatively regulate
cell cycle [8]. However, another study indicated that
TMEM158-deficient mouse embryonic fibroblasts showed
no apparent change in cellular functions, such as prolifer-
ation, senescence and oncogenic transformation [19]. The
discrepancy may due to differences in cell types and ex-
perimental models.
The exact pathway that TMEM158 may regulate in
ovarian cancers remains unclear. Our GSEA data indi-
cated that TMEM158 overexpression was positively cor-
related with the TGF-β signaling pathway (Fig. 6a). As
we all known, TGF-β signaling participates in a diverse
set of cellular processes, including cell proliferation, dif-
ferentiation, apoptosis, and specification of developmen-
tal fate [20]. The TGF-β signaling pathway has also been
considered as a promoter of tumor progression and in-
vasion. In response to elevated TGF-β levels, the tumor
cell becomes more migratory and invasive [21, 22].
BMP4 is up-regulated in human colonic adenocarcin-
oma and human colorectal cancer. HCT116 over-
expressing BMP4 exhibited enhanced migration and
invasion characteristic [23]. In ovarian cancer, TGF-β
and BMP4 are reported to play an important role in
controlling ovarian cancer metastasis [24]. In the pre-
sents study, TMEM158 knockdown significantly de-
creased the expression of TGF-β and BMP4 (Fig. 6c
and d), which indicated a relation between TMEM158
function and the regulation of TGF-β signaling in
ovarian cancer cells.
Moreover, our GSEA data indicated that TMEM158
overexpression was positively correlated with cell adhesion
molecules (Fig. 6b). It is reported that serum levels of two
important adhesion molecules, ICAM1 and VCAM1 are
significant higher in patients with colorectal cancer,
ovarian cancer, NSCLC and breast cancer [25–28].
ICAM1 and VCAM1 are considered to be important in
the process of malignant tumor growth [26, 29]. In the
presents study, TMEM158 knockdown remarkably de-
creased the mRNA and protein levels of ICAM1 and
VCAM1. The dowregulation of ICAM1 and VCAM1
may be associated with the impaired cell-matrix adhe-
sion and invasive ability (Fig. 4) of TMEM158 RNAi
cells. To our knowledge, our data firstly associated the
functions of TMEM158 with cell adhesion molecules.
Taken together, we found the overexpression of
TMEM158 in ovarian cancer cells, which was associ-
ated with cancerous transformation. Our study firstly
associates TMEM158 with the regulation of cell adhesion
molecules and TGF-β signaling pathway, thus may pro-
vide useful information for targeted therapy. Whether
TMEM158 can be used as a potential therapeutic target
for ovarian cancer remains to be further investigated.
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